Alicia Bigica

The dual orexin receptor antagonist improved sleep maintenance and total sleep time without residual next-day effects.

Fintepla, marketed by Zogenix, will be available for prescription for the rare pediatric epilepsy syndrome beginning in July 2020 through a REMS program.

The drug, previously approved for Parkinson disease psychosis, received breakthrough therapy designation for this new indication.

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

The treatment, marketed as Uplizna, is only the second approved therapy for NMOSD.

The anti-CD20 monoclonal antibody had an original PDUFA date of June 2020.

Educational sessions led by experts in multiple sclerosis will be held May 26-29, 2020.

The COMT inhibitor helps increase ON time without promoting dyskinesia.

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.

Alnylam Pharmaceuticals recently completed enrollment in the phase 3 HELIOS-A clinical trial of the drug.

Examining the underlying roles of poly adenosine diphosphate-ribose (PARP) play in the neurodegeneration of Parkinson disease.

Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism.

Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus.

Elizabeth Thiele, MD, PhD, answers a variety of questions on treating tuberous sclerosis, and the landscape of treatments available at this time.

The FDA has moved the PDUFA date for risdiplam back to August 24, 2020, as the agency works to review additional data that was made available from part 2 of the pivotal SUNFISH trial.

Both the Plegridy and Avonex drug labels no longer contain the "Pregnancy Category C" classification with the report of human pregnancy registry data.

The agency has assigned a PDUFA date of July 31, 2020, for the purified CBD treatment which has been previously approved for Dravet and Lennox-Gastaut syndromes.

Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues.

The oral selective S1P1 receptor modulator functionally inhibits S1P activity and reduces circulating lymphocytes.

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

Imad Najm, MD, director of the Cleveland Clinic Epilepsy Center, detailed the ongoing efforts to transform the way health care providers diagnose and treat patients with 1 ultimate goal in mind: improving access to high-quality care.

Based on current evidence, the Task Force was unable to recommend cognitive screening for older adults despite a recent push by the AAN to screen all adults 65 and older for thinking and memory problems.

The novel B-cell therapy has been assigned a PDUFA date of June 2020.

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Phenytoin is indicated for the treatment of tonic-clonic and psychomotor seizures in pediatric and adult patients.

Sanofi observed a dose-response relationship based on reduction of new active gadolinium-enhancing T1-hyperintense lesions after 12 weeks of treatment with SAR442168.

The study is the first placebo-controlled trial to include non-ambulant adults with spinal muscular atrophy type 2 or 3.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

The investigational Alzheimer disease treatment from Biogen will be re-administered to patients who were previously enrolled in aducanumab trials as they prepare to submit for FDA approval.